目的:探讨芪苈强心胶囊联合左西孟旦治疗充血性心力衰竭的疗效及对患者血清N端脑钠肽前体(NT-proBNP)、同型半胱氨酸(Hcy)水平及心功能的影响.方法:选取2016年1月至2018年1月河南省唐河县人民医院收治的充血性心力衰竭患者96例,按照单盲法随机分为观察组和对照组,每组48例.对照组患者给予左西孟旦治疗;在此基础上,观察组患者加服芪苈强心胶囊.比较两组患者的临床疗效,心功能指标水平[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)及左心室舒张末期内径(LVEDD)],血清NT-proBNP、Hcy水平和不良反应发生情况的差异.结果:观察组患者的总有效率为91.67％(44/48),明显高于对照组的77.08％(37/48),差异有统计学意义(P＜0.05);治疗后,观察组患者LVEF水平明显高于对照组,LVESD、LVEDD水平明显低于对照组,差异均有统计学意义(P＜0.05);治疗后,两组患者血清NT-proBNP、Hcy水平明显低于治疗前,且观察组患者明显低于对照组,差异均有统计学意义(P＜0.05);观察组、对照组患者的不良反应发生率分别为10.42％(5/48)、12.50％(6/48),差异无统计学意义(P＞0.05).结论:芪苈强心胶囊联合左西孟旦治疗充血性心力衰竭,可提高临床疗效,降低患者血清NT-proBNP、Hcy水平,改善心功能,且安全性较高.%OBJECTIVE: To probe into the efficacy of Qiliqiangxin capsule combined with levosimendan in treatment of congestive heart failure and its effects on serum N terminal-brain natriuretic peptide (NT-proBNP), homocysteine (Hcy) and cardiac function. METHODS: 96 patients with congestive heart failure admitted into Henan Tanghe County People's Hospital from Jan. 2016 to Jan. 2018 were selected and randomly divided into observation group and control group via single-blind study, with 48 cases in each. The control group was treated with levosimendan, while the observation group was given Qiliqiangxin capsule combined with levosimendan. Differences in clinical efficacy, cardiac function incidences [left ventricular ejection fraction (LVEF), left ventricular end-systolic dimension (LVESD) and left ventricular end-diastolic dimension (LVEDD) ], serum NT-proBNP, Hcy levels and incidences of adverse drug reactions between two groups were compared. RESULTS: The total effective rate of observation group was 91.67％ (44/48), which was significantly higher than that of the control group (77.08％, 37/48), with statistically significant difference (P＜0.05); after treatment, the LVEF level of observation group was significantly higher than that of the control group, while the LVESD and LVEDD levels of observation group were significantly lower, with statistically significant differences (P＜0.05); after treatment, the serum NT-proBNP and Hcy levels of both groups were significantly lower than those of before treatment, and those of the observation group were significantly lower than the control group, with statistically significant differences (P＜0.05); the incidences of adverse drug reactions of observation group and control group were respectively 10.42％ (5/48) and 12.50％ (6/48), the difference had no statistical significance (P＞0.05). CONCLUSIONS: The combination of Qiliqiangxin capsule and levosimendan can improve the clinical efficacy in treatment of congestive heart failure, reduce the NT-proBNP and Hcy levels, promote cardiac function, with high safety.
展开▼
